M
Mengzhao Wang
Researcher at Peking Union Medical College Hospital
Publications - 261
Citations - 3358
Mengzhao Wang is an academic researcher from Peking Union Medical College Hospital. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 27, co-authored 216 publications receiving 2361 citations. Previous affiliations of Mengzhao Wang include Peking Union Medical College.
Papers
More filters
Journal ArticleDOI
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): A multicentre, double-blind randomised phase 3 trial
Li Zhang,Shenglin Ma,Xiangqun Song,Baohui Han,Ying Cheng,Cheng Huang,Shujun Yang,Xiaoqing Liu,Yunpeng Liu,Shun Lu,Jie Wang,Shucai Zhang,Caicun Zhou,Xiangwei Zhang,Nobuya Hayashi,Mengzhao Wang +15 more
TL;DR: Investigating the efficacy, safety, and tolerability of the EGFR-tyrosine-kinase inhibitor gefitinib in the maintenance setting found it significantly prolonged progression-free survival compared with placebo in patients from east Asia who achieved disease control after first-line chemotherapy.
Journal ArticleDOI
Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study.
Yuankai Shi,Junling Li,Shucai Zhang,Mengzhao Wang,Shujun Yang,Ning Li,Gang Wu,Wei Liu,Guoqing Liao,Kaican Cai,Liang’an Chen,Meizhen Zheng,Ping Yu,Xiuwen Wang,Yunpeng Liu,Qisen Guo,Ligong Nie,Jiwei Liu,Xiaohong Han +18 more
TL;DR: The relatively high frequency of EGFR mutations in the mainland China subset suggest that any effort to obtain tissue sample for EGFR mutation testing should be encouraged, and is independently associated with the intensity of tobacco use and regional lymph nodes involvement.
Journal ArticleDOI
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Yi-Long Wu,Ying Cheng,Jianying Zhou,Shun Lu,Yiping Zhang,Jun Zhao,Dong Wan Kim,Ross A. Soo,Sang-We Kim,Hongming Pan,Yuh Min Chen,Chih-Feng Chian,Xiaoqing Liu,Daniel Shao Weng Tan,Rolf Bruns,J. Straub,Andreas Johne,Jürgen Scheele,Keunchil Park,James Chih-Hsin Yang,Zhe Liu,Xi Chen,Mengzhao Wang,Shiying Yu,Helong Zhang,Jian Fang,Wei Li,Chih-Hsin Yang,Gee-Chen Chang,Te Chun Hsia,Cheng-Ta Yang,Chin-Chou Wang,Byoung Chul Cho,Ki Hyeong Lee,Young-Chul Kim,Ho Jung An,In Sook Woo,Jae Yong Cho,Sang Won Shin,Jongmin Lee,Joo Hang Kim,Seung Soo Yoo,Terufumi Kato,Naofumi Shinagawa,Shao Weng Daniel Tan,Lynette Si-Mien Ngo,Kananathan Ratnavelu,Azura Rozila Ahmad,Chong-Kin Liam,Filippo de Marinis,Pierfrancesco Tassone,Amelia Insa Molla,Antonio Calles Blanco,Martin Emilio Lazaro Quintela,Enriqueta Felip Font,Anne-Marie C. Dingemans,Lynne Bui +56 more
TL;DR: Survival outcomes were similar between groups, and patients with EGFR-mutant, T790M-negative NSCLC MET overexpression or MET amplification had acquired resistance to EGFR inhibition, so tepotinib 500 mg was used as the recommended phase 2 dose.
Journal ArticleDOI
Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.
Xiao Zhao,Ru-Bing Han,Jing Zhao,Jun Wang,Fan Yang,Wei Zhong,Li Zhang,Longyun Li,Mengzhao Wang +8 more
TL;DR: The aims of this study were to determine the specific subgroups of NSCLC patients who may be the best candidates for EGFR mutation analyses using blood cfDNA and to compare the mutation statuses in plasma to those in tissues.
Journal ArticleDOI
Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma.
Jing Zhao,Minjiang Chen,Wei Zhong,Li Zhang,Longyun Li,Yi Xiao,Ligong Nie,Pei Hu,Mengzhao Wang +8 more
TL;DR: The concentration of gefitinib in CSF was low, and it was significantly related to the plasma gefithinib concentration, which may benefit patients in whom the extracranial lesions were well controlled.